RA Capital

Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.

Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.

Metagenomi, Inc. develops gene editing systems for the treatment of genetic diseases. The company was incorporated in 2016 and is based in Emeryville, California.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology.

Plexium is a drug development startup that leverages techniques from various physical-science and computational disciplines. The company develops ‘molecular glues’ that alter E3-ligase substrate recognition; inducing, inhibiting or modulating degradation of proteins for therapeutic benefit. It utilizes DNA-encoded libraries to search for molecular-glue degraders in high throughput cell-based assays. Plexium was founded in 2017 and is based in San Diego, California.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that treats it. It develops CELsignia HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELsignia MP test to diagnose 11 cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Hemab is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol. The company was founded in 1997 as Levotech, Inc. and changed its name to Agile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

At Graphite Bio, they are rapidly building a next-generation gene editing company that is driven to apply their breakthrough technology with urgency to advance gene replacement therapies and cures for people living with serious diseases. They stand apart through our ability to harness natural and highly precise cellular DNA repair machinery to achieve high efficiency, targeted gene integration to correct the underlying causes of diseases.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. They developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible. Silverback Therapeutics is building a platform technology capable of unlocking potent immuno-modulatory pathways using an established antibody-guided approach for targeting disease sites. The company's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals and Nutritionals. - The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). - The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

Jnana Therapeutics Inc. operates a drug discovery platform focused on solute carrier (SLC). The company is focusing on immunometabolism, lysosomal function, and mucosal defense, important disease pathways where SLC transporters provides target for immuno-oncology, inflammatory disorders, and neurological diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

PepGen is empowering nucleic acid therapeutics to go the distance. PepGen ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and we are advancing novel conjugate therapeutics to the clinic.

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. As of January 23, 2020, Synthorx, Inc. operates as a subsidiary of Sanofi.

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.

Alentis Therapeutics AG develops and manufactures medications to treat advanced liver diseases. It develops medications for liver fibrosis, cirrhosis, and liver cancer. The company was founded in 2019 and is based in Basel, Switzerland.

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California. As of January 23, 2020, Synthorx, Inc. operates as a subsidiary of Sanofi.

Founded in April 2006, Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Æglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes that have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing for tumor cells. The company was founded in 2013 and is headquartered in Austin, Texas.

Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. It was founded in 2020 and headquartered in Grove City, Ohio.

Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.

Acrivon Therapeutics is a biotech company specializing in drug development through early clinical treatment success.

Eliem Therapeutics, Inc. develops therapeutic drugs for the treatment of hyperexcitability disorders. The company focuses on the clinical development of analgesics for the treatment of hyperexcitability disorders, such as chronic pain using neuroscience and translational medicine. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.Cyteir Therapeutics is creating breakthrough solutions to the major challenges facing cancer researchers today. Currently in development, is the answer to the oncology triumvirate: reducing side effects, reducing therapy resistance, inducing diseased cell self destruction.

Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases.

Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical, real-time decisions that improve patient outcomes. The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible.

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.

Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

CeriBell, Inc. designs and manufactures medical devices for acquisition and interpreting electroencephalography (EEG) data in patients with various neurological conditions. It offers Ceribell EEG system that includes Ceribell EEG Headband that allows healthcare providers to accommodate various hair types and head sizes; and Ceribell EEG Recorder, a pocket-sized, battery operated recorder that provides clinical quality EEG and on-device EEG display. It serves medical staff in hospital ICUs, inpatient units, and emergency departments. CeriBell, Inc. was formerly known as Brain Stethoscope, Inc. The company was incorporated in 2014 and is based in Mountain View, California.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a routine blood test.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Be Biopharma, Inc. develops therapeutics for diseases from engineered B-cells in the immune system. It can overcome the drawbacks of current cell and gene therapies, including the inability to provide multiple doses, unpredictable chemical reactions in some individuals, and the need for chemotherapy regimens prior to cell therapies that can be dangerous to patients. The company applies its technology to diseases, including cancer, autoimmune disorders, and infectious diseases. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.

Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.

Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and improve the quality of human life. The product development portfolio of the Company includes MultiStem, a stem cell product, which is being developed as a treatment for multiple disease indications, and is being evaluated in two ongoing clinical trials, and has been authorized for use in a third clinical trial. In addition, the Company is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, and narcolepsy or other forms of excessive daytime sleepiness.

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

As of May 9, 2019, was acquired by C3J Therapeutics, Inc., in a reverse merger transaction.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

DTx Pharma, LLC, a biotechnology company, develops and commercializes fatty acid-conjugated peptide therapeutics for patients suffering from rare and chronic diseases worldwide. It offers medicines based on fatty acid motifs that deliver RNA medicines to tissues and organ systems beyond the liver. The company’s solutions are used for patients suffering from retinitis pigmentosa, Duchenne muscular dystrophy, and central nervous system problems. DTx Pharma, LLC was incorporated in 2017 and is headquartered in San Diego, California.

Merus B.V., a biomedical company, engages in the discovery and development of antibody-based biopharmaceuticals. It develops Oligoclonics technology that offers a class of human antibodies, called Oligoclonics. Oligoclonics is a concept whereby a mixture of various human therapeutic antibodies, directed to a common antigen are produced from a single cell clone. The company was founded in 2003 and is based in Driebergen, the Netherlands.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

RxSight is a medical device company that offers an intraocular lens and cataract surgery solutions. Using a proprietary light treatment that produces precise modifications in lens curvature, RxSight’s Light Adjustable Lens (RxLAL) enables doctors and patients to predictably optimize vision after cataract surgery through an office-based IOL enhancement. The company’s mission is to revolutionize the premium cataract surgery experience by allowing surgeons to partner with their patients to achieve optimized results for every unique eye. It was founded in 1997 and is headquartered in Aliso Viejo, California, United States.

Imara, Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases. WaVe maintains R&D facilities in Boston and Japan and was founded by two world-renowned scientific leaders, Gregory Verdine and Takeshi Wada. Dr. Verdine is an Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology. Dr. Wada is a professor at Tokyo University of Science, Faculty of Pharmaceutical Sciences and Department of Medicinal and Life Science.

Spero Therapeutics is developing first in class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Spero’s lead program addresses a novel target driving virulence and persistence of Pseudomonas Aeruginosa infections and other Gram-negative pathogens. The company was founded by Atlas Venture, with financing from SR One and the Partners Innovation Fund.

Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases. The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics. In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences.

EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. The company have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.

TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform. TScan Therapeutics is an owner and operator of a biotechnology company intended to develop immunotherapy treatments for cancer. The company identifies T-cell targets in a genome-wide high-throughput manner, expanding the treatment of immuno-oncology to patients who have few therapeutic options. TScan Therapeutics is harnessing novel T cell systems to extend the promise of immunotherapy. The company is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.

Pardes Biosciences is a biotechnology company that develops and commercializes direct-acting antivirals for the treatment of coronavirus. The Carlsbad, California-based company was established by Uri Lopatin in 2020.

NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.

Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.

Janux Therapeutics develops immunotherapies that generate immune responses to prevent tumors and not affecting a patient’s healthy tissue. Janux technology targets all three stages of the anti-tumor immune response. Janux Therapeutics, Inc. was founded in 2017 by David Campbell and is based in La Jolla, California.

Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

PepGen is empowering nucleic acid therapeutics to go the distance. PepGen ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and we are advancing novel conjugate therapeutics to the clinic.

Scribe Therapeutics Inc. engages in the engineering, delivery, and development of in vivo therapies and CRISPR molecules to rewrite and repair the underlying cause of genetic disorders. Its technology includes X-Editing (XE), an engineered molecule for therapeutic use and in vivo genetic modification. The company was incorporated in 2017 and is based in Berkeley, California.

Ascendis Pharma has built a high value pipeline with the aim of changing clinical treatment paradigms. Using our innovative TransCon prodrug technology platform, we continue to identify new opportunities addressing areas of high unmet medical need. TransCon is applicable to all drug classes, and is currently being used to create superior prodrugs of proteins, peptides and small molecules. Depending on choice of TransCon Carrier, either systemic or localized drug exposure is achieved, while dosing frequency is determined by the choice of TransCon Linker. The prodrugs are new chemical entities with new patent life. Product development process is de-risked, as the prodrugs release the active component in its native and unmodified form, maintaining the original drug’s well known mode of action.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Presbyopia Therapies LLC moves forward with development of its Liquid Vision drops, a temporary presbyopia-correcting therapeutic designed to last five hours or longer.

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Somatus is a healthcare company that partners with health plans, health systems, and nephrology, and primary care groups. It provides integrated care for patients with or at risk of developing kidney disease. Somatus' is vertically integrated clinical services and technology delay or prevent disease progression, improve quality and care coordination, and increase the use of home dialysis modalities and rates of kidney transplantation. The company is headquartered in McLean, Virginia, and founded by a team of world-class healthcare operators, successful entrepreneurs, and leading clinicians treating kidney disease.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

ZipLine Medical, Inc. develops and markets non-invasive skin closure solutions. The company’s product, Zip Surgical Skin Closure, is used for application in various medical specialties, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic reconstructive surgery, OB/GYN, and general surgery. Zipline Medical, Inc. was incorporated in 2007 and is based in Campbell, California. ZipLine Medical, Inc. operates as a subsidiary of Stryker Corporation.

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes.

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

We are the genome editing company specialized for mitochondrial engineering. We address unmet needs of future food supplies by creating hybrid crop plants to boost their yields to an unprecedented level. The company’s technology creates robust male sterile lines that are ideal over conventional lines because of their stability and elite backgrounds. This allows the production of non-GM hybrid seeds in crop plants that are currently mostly non-hybrid such as wheat. Our technology solution is expected to fulfill the highest level of public acceptance and aspiration.

InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.

PepGen is empowering nucleic acid therapeutics to go the distance. PepGen ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of our innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides, and we are advancing novel conjugate therapeutics to the clinic.

Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

A peloton is a team of bicyclists who achieve great efficiency of motion through cooperative action. It is also the root of platoon, a nimble military unit with capabilities that exceed the sum of its component parts. Founded by Chairman of Biochemistry Steven L. McKnight of UT Southwestern Medical Center, Peloton Therapeutics represents a unique combination of innovative science, strong financial support from the Cancer Prevention Research Institute of Texas (CPRIT), and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline, comprised of several small molecule-based programs, each with a distinct target and mechanism of action. Peloton's vision is to become a major biotech company in Dallas with a passion for discovering and developing novel cancer drugs.

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Metagenomi, Inc. develops gene editing systems for the treatment of genetic diseases. The company was incorporated in 2016 and is based in Emeryville, California.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.

Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.

Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.

Imbria Pharmaceuticals’ mission is to translate our understanding of cellular metabolism into innovative medicines that improve the lives of patients with limited or inadequate treatment options. The company was founded by doctors and launched by an all doctor executive team motivated by the promise of bringing new therapies to people in need. We are propelled by a deep scientific interest in cellular metabolism and the mitochondria, and are guided by both values and a code of business conduct built upon our commitment to always put the patients, families and communities we serve at the forefront of all that we do.

Nodexus is a Venture- and SBIR-backed biotech startup commercializing the NX One platform to address widespread unmet needs for accessible live single cell isolation in industrial/biopharma, clinical research, and academic sectors. The NX One platform consists of a low-infrastructure, low-cost hardware system and single-use disposable microfluidic cartridges tailored toward live single-cell workflows involving gene editing (e.g. CRISPR engineering), cell line/antibody development, and tumor heterogeneity studies.

Tyra Biosciences, Inc. develops small molecule therapies for the treatment of cancer. It offers therapies to combat drug resistance in cancer treatments. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.

ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.

SANUWAVE Health, Inc. is an emerging leader in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and skin, and for the separation of solids and fluid in non-medical systems. Within healthcare, SANUWAVE’s proprietary, patented Pulsed Acoustic Cellular Expression (PACE) technology emits high-energy, acoustic shock waves that restore the body’s normal healing processes. This activates biologic signaling which leads to tissue repair and regeneration and blood vessel growth – revascularization and microcirculatory enhancement. SANUWAVE has three devices that employ the PACE technology. The lead device for the global wound care market, dermaPACE®, is approved for use outside the United States (CE Marked) for advanced wound care indications and is currently being studied in a U.S-based supplemental pivotal clinical trial for diabetic foot ulcers. The orthoPACE® device is CE Marked for orthopedic and musculoskeletal indications. OssaTron®, the Company’s legacy device, is approved by the FDA for multiple orthopedic conditions which have failed to respond to conservative treatment. In addition, SANUWAVE has patented the use of its shock wave technology in non-medical fields, including energy (improved/enhanced oil recovery), water (purification), food (bacterial reduction), and industrial effluent (particulate separation), and is working toward licensing/partnership relationships.

Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

AN2 Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of novel medicines targeting infectious diseases. The company focuses on developing a clinical-stage antibacterial compound. It has a strategic partnership with Brii Biosciences. The company was incorporated in 2017 and is based in Menlo Park, California.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Farcast is a clinical diagnostic company whose mission it is to illuminate personal treatment truth of a cancer patient. The Farcast technology core is a human tumor micro-environment that enables oncologists and drug developers to test individual tumors to determine treatment response profiles. The company has its headquarters in Boston in Massachusetts, and operates a lab in Bangalore in India.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

ARS Pharmaceuticals is a stealth pharmaceutical company that developed a novel intranasal epinephrine spray with a unique absorption technology that could be easy-to-use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications and insect bites that could lead to life-threatening anaphylaxis.

Ocelot Bio brings new treatment options to patients with severe liver disease. The company was founded in 2020 and is headquartered in San Diego, California.

Emergence Therapeutics AG develops novel antibody drug conjugate (ADC) immuno-therapeutics to treat high need cancers. The company was incorporated in 2019 and is based in Duisburg, Germany.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

Ansa Biotechnologies, Inc. develops a novel DNA synthesis technology based on enzymes. It offers built DNA fragments, such as oligonucleotides. The company also provides a new technology to manufacture DNA that is used in biological research and biotechnology, including therapeutics, diagnostics, and biomanufacturing. The company was incorporated in 2018 and is based in Berkeley, California.

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich’s ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Solana Beach, California.

MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

GentiBio, Inc. develops engineered regulatory T cells (EngTregs) for the treatment of autoimmune, alloimmune, autoinflammatory, and allergic diseases. Its proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. The company was incorporated in 2020 and is based in Boston, Massachusetts. It has additional locations in Israel and Seattle, Washington.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.

Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Tyra Biosciences, Inc. develops small molecule therapies for the treatment of cancer. It offers therapies to combat drug resistance in cancer treatments. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients’ muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases.

RxSight, Inc. develops light adjustable lens that enables doctors and patients to predictably optimize vision after cataract surgery through an office based intraocular lens enhancement. It offers RxLAL that enables surgeons to precisely reshape the lens based on the exact amount of visual correction and optimization needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was founded in 1997 and is based in Aliso Viejo, California.

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Lantos Technologies is the only FDA-cleared 3D ear scanning system that enables custom, in-ear products with superior comfort, sound quality, and performance. Our technology enables the efficient and effective delivery of customized hearing aids and other hearing-related products.

Affinia Therapeutics is a developer of a platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies intended to develop medicines for devastating diseases. The company leverages synthetic and systems biology combined with high-throughput screening and tissue and single-cell resolution for people affected by muscle and central nervous system (CNS) diseases with significant unmet needs, thereby providing medical professionals with the rational design of novel vectors and gene therapies with remarkably improved properties.

Saniona is a research and development company with low burn rate, a world class team and high ambitions.

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

Eliem Therapeutics, Inc. develops therapeutic drugs for the treatment of hyperexcitability disorders. The company focuses on the clinical development of analgesics for the treatment of hyperexcitability disorders, such as chronic pain using neuroscience and translational medicine. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.

Acumen Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics and diagnostics for treating Alzheimer’s disease and related neurodegenerative conditions. The company focuses on developing ADDL-Select antibodies that target soluble Aß oligomers, which are main causes in the disease process. It also uses a sensitivity assay to measure soluble Aß oligomer levels in the cerebrospinal fluid in patients to be enrolled in clinical trials. Acumen Pharmaceuticals, Inc. was founded in 1996 and is based in Livermore, California.

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Ventus Therapeutics U.S., Inc., a biopharmaceutical company, develops novel therapeutics that target the innate immune system to treat autoimmune diseases, inflammatory diseases, and cancer. It offers structural immunology platform that employs protein engineering to solve molecular structures, enable novel binding and functional screening assays, and power structure-based modeling. The company develops small-molecule medicines to target proteins in the inflammasome and nucleic acid sensing signaling pathways. The company was incorporated in 2019 and is based in Natick, Massachusetts. It has an additional location in Montreal, Canada.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.

Life sciences company focused on the discovery, development and commercialization of treatments for infertility

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. tHEY were founded on breakthrough computationally-designed virus-like particle technology, exclusively licensed for a variety of infectious disease indications from the Institute for Protein Design at the University of Washington.

New Equilibrium Biosciences provides a platform that reveals opportunities for structure-based design by learning biophysics with AI.

Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases. Adagio Medical is committed to providing electrophysiologists innovative cryoablation catheters that create safe, continuous, transmural lesions to treat cardiac arrhythmias anywhere in the heart, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. The company was founded in 2011 and is based in Laguna Hills, California.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

Century Therapeutics, Inc. engages in the development of induced pluripotent stem cell- (iPSC) based drugs for the treatment of hematologic and solid malignancies. The use of iPSC enables multiple rounds of cellular engineering to produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply allogeneic, homogeneous therapeutic products. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Akouos is a biotechnology company focusing on restoring and preserving hearing. The company leverages adeno-associated viral (AAV) vector-based gene therapy in order to restore and preserve hearing in genetically-defined patient populations in a range of forms, from a single genetic mutation to ototoxic drug exposure and to the aging process, enabling the healthcare industry to treat sensorineural hearing loss in an efficient manner.

Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novel antibody-based immunotherapies. It was founded in 2019 and is based in Boston, Massachusetts.

Kira Pharmaceuticals is a developer and researcher of antibody drugs and immunoantibody therapy. The company is mainly engaged in the research, development and production of antibody medicine to treat various diseases, providing healthcare patients with better treatments and therapy.

G1 Therapeutics is a clinical-stage company developing novel cancer therapies. It was founded in 2008 by Drs. Norman Sharpless and Kwok-Kin Wong to capitalize on discoveries made and patented by Dr. Sharpless’ lab at the University of North Carolina at Chapel Hill, and subsequently licensed to G1 Therapeutics. Trilaciclib is an investigational therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer.

Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts ; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was founded in 2016 and is headquartered in South San Francisco, California.

Antera Therapeutics is a biotechnology company that specializes in creating therapies that will prevent allergy development in children. It helps families introduce peanuts into infants'​ diets in a structured and convenient way. It was founded in 2014 and headquartered in Boston, Massachusetts.

Eliem Therapeutics, Inc. develops therapeutic drugs for the treatment of hyperexcitability disorders. The company focuses on the clinical development of analgesics for the treatment of hyperexcitability disorders, such as chronic pain using neuroscience and translational medicine. The company was incorporated in 2018 and is based in Boston, Massachusetts.

CiVi Biopharma is a clinical stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development including Intravenous Iloprost in Phase 3 trials for treatment of Systemic Sclerosis.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Seres Health is a clinical-stage therapeutics company focused on discovering and developing drugs to treat diseases of the microbiome. The biology of the microbiome is driven by ecologies—the functional collections of various organisms—which are central to health and disease. Seres is developing Ecobiotic™ therapeutics to treat diseases that have an underlying microbiome biology. Our first clinical program is in the treatment of Clostridium difficile infection.

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases.

Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

GentiBio, Inc. develops engineered regulatory T cells (EngTregs) for the treatment of autoimmune, alloimmune, autoinflammatory, and allergic diseases. Its proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. The company was incorporated in 2020 and is based in Boston, Massachusetts. It has additional locations in Israel and Seattle, Washington.

Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.

Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

SeLux Diagnostics, Inc. develops a next generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious disease. It develops a synthetic amplifier technology equipment that breaks the speed versus complexity tradeoff in AST testing and dramatically improves patient care. SeLux Diagnostics, Inc. was founded in 2014 and is based in Charlestown, Massachusetts.

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Strongbridge Biopharma’s primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of opioid use disorder. We are dedicated to advancing next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of opioid use disorder faced by patients, healthcare professionals, payers, and society.

Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is an oncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer.

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

Clementia is a clinical-stage company innovating treatments for people with ultra-rare bone disorders. The company develops disease-modifying treatments for patients suffering from debilitating bone and other diseases with a high unmet medical need. The company's lead product candidate, palovarotene, is an oral small molecule that has shown potent activity in preventing abnormal new bone formation as well as fibrosis in a variety of tissues. Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, Quebec.

Cytek Biosciences provides solutions that enable scientists to rapidly, efficiently obtain deep biological insights through high quality, high parametric datasets. Cytek manufactures and supplies flow cytometry products and services. Cytek’s compact, affordable instruments, and wide-ranging support offerings are used by researchers and clinicians all over the world. Cytek is focused on accelerating the adoption of flow cytometry to fuel scientific discovery. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that completed a Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company’s lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Verve Therapeutics, Inc. develops therapies for editing the adult human genomes. It utilizes human genetic analysis and gene-editing technology for developing therapies to reduce the risk of coronary artery diseases. The company serves the biotechnology and health care sectors. It has a strategic alliance with Beam Therapeutics for developing delivery technologies against cardiovascular targets; and Verily, for the development of gene editing delivery vehicles. Verve Therapeutics, Inc. was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in September 2019. The company was founded in 2018 and is based in Cambridge, Massachusetts with a research facility in Philadelphia, Pennsylvania.

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and headquartered in San Francisco, California.

Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS. Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Cybin Corp is a Mushroom Life Sciences company advancing psychedelic and medicinal mushroom research, product development and IP through a multi-tiered pharmaceutical and nutraceutical approach. The company is launching psilocybin-based products in jurisdiction’s where the substance is not banned alongside structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system. The company was incorporated in 2015 and is based in Newton, Massachusetts.

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.

CANbridge Life Sciences Ltd., a bio-pharmaceutical company, develops and commercializes healthcare products in China and North Asia. It offers products for oncology and rare diseases. The company was founded in 2012 and is based in Beijing, China with additional offices in Shanghai, China; Cambridge, Massachusetts; Taipei, Taiwan; and Tsim Sha Tsui, Hong Kong.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Novavax is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated the development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

Sojournix, Inc. operates a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women’s health and neuroendocrine disorders. The company developing SJX-653: a novel and selective neurokinin-3 (NK3) antagonist as a non-hormonal therapy for moderate to severe vasomotor symptoms. Sojournix, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

Quench Bio is a developer of gasdermin biology drugs designed to treat severe inflammatory diseases.The company leverages insights into gasdermin biology and innate immunity to develop medicines with lead compounds that target and inhibit the pore-forming protein that mediates the release of inflammatory cytokines, alarmins, DNA and NETs, enabling patients to get relief from inflammatory diseases.

Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

As of January 6, 2009, Genelabs Technologies Inc. was acquired by SmithKline Beecham Corporation. Genelabs Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of infectious disease therapies to improve human health. The company's product pipeline consists of infectious disease projects focusing on Hepatitis C virus infection; and late-stage clinical assets, including an investigational vaccine for hepatitis E virus that is being developed by GlaxoSmithKline; and Prestara, an investigational drug for systemic lupus erythematosus. It has license and collaboration agreement with the Novartis Institutes for BioMedical Research for HCV polymerase non-nucleoside discovery research. Genelabs Technologies also has a collaborative research agreement with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to discover and develop compounds that target the hepatitis C virus. The company was founded in 1983 and is headquartered in Redwood City, California.

Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases.

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Attune Pharmaceuticals, Inc. is a biotechnology research and development company. The company develops novel oral small molecule therapeutics for treatment of rare diseases. Attune Pharmaceuticals, Inc. was incorporated in 2015 and is based in New York, New York.

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.

Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Qvella is a molecular diagnostics company founded in 2009 by a group of scientists and engineers with the primary goal of dramatically reducing time to results in microbiology. This objective, widely recognized as highly desirable, has proved elusive yet holds the promise of revolutionizing how medicine is practiced by offering actionable results in clinically relevant time frames to improve patient outcomes and save lives. Qvella's Field Activated Sample Treatment (FAST™) technology utilizes a novel electrical lysing and sample treatment technique we call e-lysis™; enabling direct and fully-automated rapid detection of infectious agents from unenriched biological samples.

DiCE Molecules Corp. develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its technology allows the extension of directed evolution to provide organic compounds as the output. The company also develops a methodology for translating DNA encoded information directly into organic compounds in essence roboticizing the laborious processes of medicinal chemistry. Its technology is used in the fields of pharmaceuticals, agriculture, and materials sciences. DiCE Molecules Corp. was incorporated in 2013 and is based in Menlo Park, California.

Calimmune, Inc., a clinical-stage human immunodeficiency virus (HIV) gene medicines company, develops cell-based therapies for HIV. The company offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. It also focuses on developing products to address the needs of various types of individuals at different states of HIV infection and with different levels of treatment experience. The company was founded in 2000 and is based in Tuscon, Arizona. As of August 31, 2017, Calimmune, Inc. operates as a subsidiary of CSL Behring LLC.

Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Coherus Biosciences was established in 2010 and is headquartered in Redwood City, California.

Civitas Therapeutics is a biopharmaceutical company that focuses on developing pulmonary delivery therapies. The Company develops therapeutics for the treatment of central nervous system and respiratory disorders. It serves patients throughout the United States.

WhiteSwell Limited provides cardiology services. The company offers treatment for acute decompensated hearth failure (ADHF). Its treatment is a catheter-based approach to remove excess tissue fluid in patients with ADHF, without comprising renal function. The company was founded in 2014 and is based in Galway, Ireland with additional offices in Shefayim, Israel and Palo Alto, California

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson’s disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.

ZipLine Medical, Inc. develops and markets non-invasive skin closure solutions. The company’s product, Zip Surgical Skin Closure, is used for application in various medical specialties, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic reconstructive surgery, OB/GYN, and general surgery. Zipline Medical, Inc. was incorporated in 2007 and is based in Campbell, California. ZipLine Medical, Inc. operates as a subsidiary of Stryker Corporation.

Xenikos aims to develop a new medicine, based on the action of antibodies that enables patients suffering serious immune diseases, or rejection after transplantation, to reset their immune system quickly and efficiently. Xenikos strives to develop new, innovative immunotherapy medicines to help restore patients’ health and save lives.

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.

Legend Biotech is a biopharmaceutical company bringing impactful innovations in cell therapy, and accelerating the science. They are committed to improving the lives of patients worldwide. They are also steadfast in their goal to develop innovative cellular therapies that bring us closer to a cure. It develops cell therapies from discovery through commercialization.

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

AgriMetis, LLC engages in the research, development, and production of crop protection products. It focuses on developing fungicides, herbicides, insecticides, and nematicides from natural products. The company was incorporated in 2014 and is headquartered in Lutherville, Maryland with an additional office in Research Triangle Park, North Carolina. It also has a laboratory in Gaithersburg, Maryland.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

CANbridge Life Sciences Ltd., a bio-pharmaceutical company, develops and commercializes healthcare products in China and North Asia. It offers products for oncology and rare diseases. The company was founded in 2012 and is based in Beijing, China with additional offices in Shanghai, China; Cambridge, Massachusetts; Taipei, Taiwan; and Tsim Sha Tsui, Hong Kong.

CellScape Corporation (formerly Saryna Medical Corp) is a privately funded company headquartered in Newark, California, in the heart of the biotech corridor of the San Francisco Bay Area. The Company has developed whole fetal cell technology to transform prenatal genetic testing using a simple blood test. Their vision is to make comprehensive prenatal genetic testing available to every woman without requiring an invasive procedure that might put the fetus at risk. Their leadership team is accomplished in bringing innovative, cost-effective medical and molecular diagnostics to market.

Ervaxx is pioneering the use of Dark Antigens™ to deliver targeted off-the-shelf cancer vaccines and other immunotherapies for treating and preventing cancer. Their Dark Antigens™ derive from vast untapped expanses of genetic ‘dark matter’ beyond the normal coding regions of the genome, which are generally silenced in normal tissue but are selectively activated in cancer.

Werewolf Therapeutics operates as an oncology biotherapeutics company advancing a pipeline of transformative cancer treatments. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response and unleash an attack on cancer cells.

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

At Janssen, the pharmaceutical companies of Johnson & Johnson, our mission is to transform individual lives and change fundamentally the way diseases are managed, interpreted, and prevented. Bringing solutions and advancing science for the benefit of patients. They work with today’s informed and empowered patients to ensure our solutions are designed for and reach the people who need them. They work for change that will improve access to medicines: the best available treatment at an affordable price. That’s why they at Janssen strive to provide access to effective and affordable medicines and related health care services across the world.

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Bolt Biotherapeutics, Inc., a biotechnology company, develops immune-stimulating antibody conjugates (ISAC) for treating cancer. The company’s Boltbody platform includes ISAC and conjugates tumor-targeting antibodies to powerful immune stimulants, such as TLR agonists that convert cold tumors into immunologically hot tumors, as well as eliminates tumors. The company develops BDC-1001 as a monotherapy for patients with HER2-expressing solid tumors. Bolt Biotherapeutics, Inc. was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. The company was incorporated in 2015 and is based in Redwood City, California.

Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.

Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company’s lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients’ muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrate that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries. LianBio collaborates with world-class partners across a diverse array of therapeutic and geographic areas to build out a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision-based therapeutics.

Dignify Therapeutics is a drug development company focused on delivering novel drug therapies for bladder and bowel disorders in spinal cord injured, multiple sclerosis and similar patient populations. By combining novel pharmaceutical agents with drug delivery technology, Dignify Therapeutics will redefine the treatment of these disorders and restore the dignity of voluntary excretory function for these patients. The company was founded in 2013 and is headquartered in Raleigh, North Carolina.

Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.

Natera is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.

Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of proprietary, late-stage pharmaceutical products. These products address the growing problems associated with non-medical use and abuse of prescription drugs through formulation based improvements protected by intellectual property (IP). Collegium is focused on building a portfolio of products for the treatment of chronic pain that possess tamper-resistant features and provide extended-release delivery using its patent-protected DETERx formulation platform.

WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases. WaVe maintains R&D facilities in Boston and Japan and was founded by two world-renowned scientific leaders, Gregory Verdine and Takeshi Wada. Dr. Verdine is an Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology. Dr. Wada is a professor at Tokyo University of Science, Faculty of Pharmaceutical Sciences and Department of Medicinal and Life Science.

Nivalis Therapeutics is developing a novel class of disease-modifying therapies that are designed to preserve intracellular GSNO (S-nitrosoglutathione), an endogenous molecule with cell signaling effects that are implicated in the pathophysiology of cystic fibrosis (CF).The Company’s lead candidate, N91115 initially targets patients with the F508del mutation, the most common disease-causing mutation in CF. Nivalis Therapeutics is dedicated to making a difference in the lives of patients with cystic fibrosis and their families. The company was founded in 2007 and is headquartered in Boulder, Colorado, United States.

Protagonist Pty Ltd. develops novel therapeutics for inflammatory and metabolic conditions. The company also involves in the discovery of peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. In addition, it focuses on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions), and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity. Protagonist Pty Ltd was formerly known as Cytokine Mimetics Pty Ltd. The company was founded in 2001 and is based in Brisbane, Australia. Protagonist Pty Ltd operates as a subsidiary of Protagonist Therapeutics, Inc.

Be Biopharma, Inc. develops therapeutics for diseases from engineered B-cells in the immune system. It can overcome the drawbacks of current cell and gene therapies, including the inability to provide multiple doses, unpredictable chemical reactions in some individuals, and the need for chemotherapy regimens prior to cell therapies that can be dangerous to patients. The company applies its technology to diseases, including cancer, autoimmune disorders, and infectious diseases. The company was incorporated in 2020 and is based in Cambridge, Massachusetts.

ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Ocera is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's HE clinical development efforts include a recently completed Phase 2b clinical trial, STOP-HE, which evaluated the safety and efficacy of intravenously-administered OCR-002 in resolving neurocognitive symptoms of acute HE in hospitalized patients with elevated ammonia. Ocera is preparing to meet with the FDA later this year to review the IV program and discuss potential development paths forward.

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

ZS Pharma is a privately held specialty pharmaceutical company based in Coppell, Texas, and Menlo Park, CA. Its core focus is the research and development of highly selective ion-trap therapies to treat serious medical conditions. The company'ss therapeutic candidate, ZS-9, is a novel treatment for hyperkalemia, a life-threatening condition that affects patients with chronic kidney disease, hypertension, diabetes, and/or chronic heart failure. Hyperkalemia is characterized by abnormally high concentrations of potassium in the blood. ZS-9 is currently being tested in late-stage clinical trials.

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Adeo Health Science, Inc. develops and produces Aralyte, an organic food for special dietary use that offers parents a structured means of implementing the LEAP (learning early about peanut allergy) regimen. Its Aralyte contains natural distilled peanut extract and Vitamin D for babies just starting solid food. The company offers its products online. Adeo Health Science, Inc. was formerly known as Antera Therapeutics, Inc. and changed its name to Adeo Health Science, Inc. in September 2018. The company founded in 2014 and is based in Boston, Massachusetts.

Realm Therapeutics is a biopharmaceutical company passionately committed to leveraging its proprietary technologies to protect and improve the health of adults and children. The Company's drug development focus, utilizing its immunomodulatory formulations, is targeted initially on developing small molecule therapies in inflammatory diseases with potential application in dermatology and ophthalmology, and the potential for broad applicability across a number of other diseases.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead program is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of metastatic or locally advanced, ER-positive, and human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

AavantiBio, Inc. engages in developing gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. It focuses on Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company was incorporated in 2019 and is based in Gainesville, Florida.

Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing FT-2102, an oral selective small molecule investigational agent that is designed to bind to and inhibit mutated IDH1 enzymes, which is being evaluated in a Phase 2 trial for relapsed/refractory AML, as well as an exploratory Phase 1 trial for glioma; and FT-4101 and FT-8225, which are selective fatty acid synthase inhibitors. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data revolution: truly personalized therapies that improve outcomes and shift cancer to a manageable condition.

Day One Biopharmaceuticals is a biotechnology company focused on developing new cancer therapies for patients of all ages. The company understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. They develop new therapies that meet the critical needs of people of all ages living with cancer starting from the biology of childhood cancer. Day One Biopharmaceuticals also focuses its efforts to bring the best medicines to families receiving the life-altering news of a new cancer diagnosis and the need for a treatment plan. It prioritizes programs that can be rapidly brought to market for both younger and older patients. The company's goal is to license and acquire the most promising products from research institutions as well as for biotechnology and pharmaceutical companies. Day One Biopharmaceuticals was founded in 2018 and is headquartered in South San Francisco, CA, USA.

Terapore Technologies, Inc. develops a membrane technology for research and development scale bioprocessing applications. Its technology facilitates the purification of biological fluids. The company was incorporated in 2013 and is based in South San Francisco, California.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Ra Pharma is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma is leveraging its ability to rapidly generate drug candidates to develop its own portfolio of products and partnerships focused on intracellular protein-protein interactions and other innovative approaches to addressing unmet medical needs. It was founded in 2008 and headquartered in Cambridge, Massachusetts.